BRD2 and myelofibrosis: This compound is an experimental myelofibrosis and cancer drug [43] (clinicaltrials.gov, NCT04454658, accessed July 21, 2023) that acts as an inhibitor of BET bromodomain proteins, specifically BD2 domain of BRD2, BRD3 and BRD4.